Healthcare Market Forecasts: GLP-1 Drugs, HIFU, and AI Precision Medicine Show Strong Growth

The global obesity and diabetes drugs market is projected to expand through 2035, driven by GLP-1 receptor agonists, while Europe's high-intensity focused ultrasound (HIFU) market is expected to reach USD 65.57 billion by 2033 and its AI in precision medicine market to grow at a 31.3% CAGR from 2024 to 2029. The obesity and diabetes drugs market is undergoing a fundamental transformation, shifting from a purely clinical, prescription-driven category toward a consumer-facing, benefit-led wellness segment.

The baseline scenario for the obesity and diabetes drugs market from 2026 to 2035 projects sustained expansion, transitioning from a period of explosive growth for novel agents to a phase of broader, steady adoption and market penetration. The core driver remains the high and growing global prevalence of type 2 diabetes and obesity, compounded by an aging population and sedentary lifestyles. Growth will be modulated by payer cost-containment pressures, the gradual entry of biosimilars, and regulatory frameworks governing off-label use and direct-to-consumer promotion. Channel dynamics are intensifying, with traditional pharmacy distribution facing pressure from direct-to-consumer telehealth platforms and online subscription models. The market will see a bifurcation in brand strategy: established pharmaceutical giants will leverage deep clinical heritage and extensive provider networks, while agile, consumer-focused entrants build lifestyle brands centered on outcomes and digital support. Supply chain robustness, particularly for complex biologics requiring cold-chain logistics, will be a critical factor, potentially favoring large, integrated manufacturers. Geographically, North America will continue as the premium innovation and branding epicenter, Europe will balance innovation with strict cost-effectiveness reviews, and the Asia-Pacific region will emerge as the largest volume growth pool.

In the glycemic control segment, demand is currently driven by standard oral agents like metformin but is rapidly pivoting toward newer injectable and oral classes with superior efficacy and ancillary benefits. Through 2035, the mechanism of demand will shift from simply lowering HbA1c to a comprehensive cardiorenal-metabolic risk reduction strategy, supported by updated clinical guidelines favoring GLP-1 receptor agonists and SGLT2 inhibitors for patients with established cardiovascular disease or high risk. Major trends include a guideline-driven shift from metformin-centric to GLP-1/SGLT2-first approaches for high-risk patients, growing use of fixed-dose combinations, and increasing focus on preserving beta-cell function and achieving remission in early-stage diabetes. The obesity segment is experiencing a paradigm shift, moving from a niche, often stigmatized treatment area to a mainstream consumer health category, powered by drugs demonstrating 15% or greater weight reduction. Key demand indicators include expansion of public and private insurance coverage for anti-obesity medications, prescription volumes through telehealth platforms, and patient persistence rates beyond one year. Representative participants in the market include Novo Nordisk, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Merck & Co, and Sanofi.

Europe's high-intensity focused ultrasound (HIFU) market was valued at USD 35.04 billion in 2024 and is expected to reach USD 65.57 billion by 2033, expanding at a compound annual growth rate of 7.21% from 2025 to 2033. HIFU is an image-guided, non-invasive treatment modality that uses focused ultrasound energy to generate heat at a precise point inside the body, destroying targeted tissue such as tumors or fibroids while sparing surrounding healthy structures. Unlike conventional surgery or radiation therapy, HIFU does not require incisions or ionizing radiation, and procedures are typically associated with shorter recovery times, fewer complications, and reduced hospital stays. In Europe, HIFU has found strong adoption in oncology, particularly for prostate, liver, and pancreatic cancers, as well as in gynecology for uterine fibroids, and has recently gained momentum in neurology and aesthetic medicine. Germany, France, and the United Kingdom are leading the region in clinical trials, hospital adoption, and research collaborations. Market growth is driven by the rising burden of cancer, uterine fibroids, and neurological disorders, growing demand for non-invasive therapies, advancements in imaging technologies such as MRI-guided HIFU, and expanding applications in aesthetics, including non-surgical skin tightening, facial lifting, and body contouring.

Europe's AI in precision medicine market was valued at $231.02 million in 2024 and is projected to reach $1,185.99 million by 2029, representing a compound annual growth rate of 31.3%. The market is driven by increasing healthcare digitalization, substantial government funding for AI research, and growing adoption among leading medical institutions. Europe's comprehensive regulatory frameworks, including GDPR and MDR compliance standards, create a trusted environment for AI adoption in clinical settings. European healthcare systems are rapidly integrating machine learning algorithms and advanced data analytics into diagnostic and treatment protocols, enabling personalized medicine approaches and improving patient outcomes and operational efficiency. The market is primarily driven by AI applications in oncology, cardiology, and genomics, where diagnostic accuracy and treatment personalization are critical. Within the market, software is the largest component segment, and image analysis is the fastest growing tool segment. Leading pharmaceutical companies and biotech firms are establishing innovation hubs across major European markets to capitalize on this growth opportunity.